ABSTRACT
SAŽETAK

Jasno odvajanje dva najčešća oblika dilatacionih kardiomiopatija veoma je važno zbog različite prognoze i terapijskog pristupa. Dobutamin stres ehokardiografi ja se čini neinvazivnom metodom izbora za njihovo jasno diferenciranje. Veliki uticaj operatera i interpretaciji testa doveo je do širokog intervala dijagnostičke tačnosti ovog testa. Frakciona rezerva protoka (FFR) je nova invazivna metoda za procenu stenoze koronarnih arterija odgovornih za ishemiju miokarda. Odluka o značajnosti lezija na koronarnim krvnim sudovima na osn-
INTRODUCTION
The ability of numerous non-invasive tests to detect coronary diseases of patients with dilated cardiomyopathy has been evaluated (1) . Determining the presence of coronary disease in a patient is important not only for therapy but also for prognosis. Echocardiography is widely used in researching dilated cardiomyopathies. Unfortunately, regional fall-out of wall mobility in nonischaemic dilated cardiomyopathies and global dysfunction of patients with ischaemic cardiomyopathies frequently prevents the identification of coronary disease.
Several non-invasive techniques have been used to differentiate these two forms of dilated cardiomyopathy, but their differentiation has been limited due to numerous controversial results (2) . The work of Shapr and associates was the first to demonstrate the higher sensitivity and specificity of dobutamine stress echocardiography test in patients with dilated cardiomyopathy (3). This report and the majority of studies (4) have been dominated by patients with ischaemic cardiomyopathy and data on myocardial infarction (MI). Few researchers have focused their work on segmented contractility in dobutamine stress echocardiography tests in patients with primary dilated cardiomyopathy (3, 5, 6) . Wide intervals of sensitivity, specificity and diagnostic accuracy can be generated due to inaccurate interpretations of coronary results. Interpreting angiographic stenosis from a 50% or even 75% lumen diameter as significant without functional assessment through FFR appears to be unacceptable today (7, 8) . In our research, we have concluded that the normal response of the left chamber to an elevated dose of dobutamine in the absence of coronary disease is an increase in contractility. However, if significant coronary disease is present, contractility should initially increase after dobutamine infusion, and if the dose of dobutamine is high, contractility should significantly worsen due to a provocation of myocardium ischaemia. The goal of our study was to define a pattern for differentiating the most severe forms of dysfunction and dilatation of the left chamber (LC) of unknown cause during the dobutamine stress echocardiography test, based on characterisation of segmental contractility before and during dobutamine infusion in patients with ischaemic and nonischaemic (primary) dilated cardiomyopathy.
MATERIAL AND METHODS
During the period 2010-2012, the Clinic for Cardiology KC Kragujevac performed dobutamine stress echocardiography in 50 patients with dilated cardiomyopathy, with the addition of atropine in 15 patients. All patients were subjected to a coronary angiography procedure, and, for patients with stenosis > 50%, FFR measurements were performed. Significant stenosis was indicated by a measurement value <0.80.
Analysis of studied population. The study included patients with dilated cardiomyopathy without histories of myocardial infarction. To be included, patients needed to have the following: optimal ultrasound images, end-diastolic diameter (EDD) ≥ 6.0 cm (M-mode), ejection fraction (EF) <40% (Simpson method). Patients were excluded based on the existence or a history of the following: congestive heart failure, unstable angina, significant ventricular arrhythmias, LV aneurysm, severe valvular disease appliances and any contraindications to dobutamine infusion or the administration of atropine (7) . DobAtro SET protocol. The protocols for DobAtro SET vary depending on the facility in which the test is performed, with differences in the dobutamine dose (20-40 mg/kg/min), atropine dose (0-2 mg) and administration time of various dobutamine doses (2-8 min). The most widely used protocol for DobAtro SET, which is applied in our practice and was used in this work, include the following: after a baseline echocardiographic study, dobutamine is administered intravenously at an initial dose of 5 μg/kg/ min for 3 minutes and is then increased to 10 μg/kg/min, 20 μg/kg/min, 30 μg/kg/min, and up to a maximum of 40 mg/kg/min over three minute intervals at each dose. If the submaximal frequency was not achieved (calculated by the formulas 220 -age x 0.85 for men and 200 -age x 0.85 for women), we administered atropine at a dose of 0.25 mg to a maximum dose of 2 mg. Patient echocardiograms were continuously monitored, and the results were recorded on three-channel electrocardiograph devices after the end of each dobutamine dosing interval and 6 min after the test. The echocardiograms were continuously monitored by videotape recordings of the final minute of each stage and 5 min after the test. Longitudinal and transverse sections of the parasternal view and the apical view with four or
ABBREVIATIONS
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Interpretation of echocardiographic results. Segmental myocardial contractility was assessed according to the recommendations of the American Society of Echocardiography, based on which the left ventricle is divided into 16 segments. The left ventricular wall motion sum index (WMSI) was calculated for each stage of the test by adding together the points of each segment. The contractility of each segment was determined semiquantitatively by scoring from 1 to 4, wherein normal contractility is assessed as 1 (> 5 mm endocardial movement), hypokinesia as 2 (> 5 mm endocardial movement), akinesia as 3 (lack of movement or endocardial movement < 2 mm) and dyskinesia as 4 (paradoxical outward movement in systole). A negative DobAtro SET was defined as uniformly increasing mobility of walls and systolic thickening with telesystolic reduction of the left ventricular volume. A positive DobAtro SET was defined as the occurrence of failure emerging in segmental contractility or worsening failure in at least one segment. Reading of the results was performed by two independent echocardiographers who were not familiar with the coronary angiographic findings.
Stress electrocardiography. Before the test, and after each stage of the test, electrocardiographic recordings were made on a three-channel electrocardiograph. The EKGs were interpreted as normal, ischaemic or non-diagnostic. Ischaemic changes were defined by the presence of ST segment depression > 0.1 mV or > 0.2 mV in the leads, with ST abnormalities at rest. The electrocardiograms were interpreted as non-diagnostic if blockage of the left branches was present after digitalis therapy or ST depression > 2 mm was observed at rest.
Coronary angiography. Visual assessment of stenosis diameter expressed in % was performed by two experienced angiographists. Significant coronary stenosis with a > 50% reduction in the absolute lumen diameter of the main epicardial arteries or their main branches was the indication for FFR measurements. A measured FFR value < 0.80 indicated the presence of significant coronary stenosis. Patients with verified significant contraction of 1 main coronary artery were considered to have ischaemic dilated cardiomyopathy.
Statistic data analysis. The following descriptive statistics methods were used to describe the general characteristics of patients in the observed group: absolute numbers and proportions, central tendency measures (average value) and variability measures (standard deviation). Student's t-tests were used to compare the average observed numeric values between two groups. When a characteristic's distribution prevented the application of parametric statistics, a Mann-Whitney test was used. Two-factor variance analysis was used to compare the average number of segments for certain categories of wall mobility between the two groups in every observation period. Based on the test results and given diagnosis, test sensitivity and specificity were determined, as were positive and negative predictive values.
RESULTS
Clinical, electrocardiographical and basic echocardiographical data. The data obtained for the tested groups are shown in Table 1 . No statistically significant differences in the anthropometric values, echocardiographical or echocardiographical data were observed between groups. A statistically considerably higher frequency of angina pectoris was observed in patients with ischaemic cardiomyopathy. Smoking and inheritance were the dominant risk factors in the ischaemic and nonischaemic dilated cardiomyopathy groups, respectively.
Results of the stress test and side effects. When comparing patients with ischaemic and nonischaemic dilated cardiomyopathy, no statistically significant differences were found in the average dobutamine dose, atropine dose, achieved submaximal frequency, systolic blood pressure or double product. We also did not observe any considerable differences in the appearance of chest pain, dyspnoea or ST segment modifications. Chest pain was registered in 4 and 3 patients with ischaemic and nonischaemic dilated cardiomyopathy, respectively. Dyspnoea was reported in 3 patients with nonischaemic dilated cardiomyopathy, compared to 2 patients in the other group. Modifications in the ST segment were not observed in nonischaemic dilated cardiomyopathy patients but were found in 2 patients from the first group (Table 2) .
Results of echocardiographic monitoring of LK wall mobility. The segment LK classification results were tested using two-factor and repeated measures variance analysis at rest, after a low dose of dobutamine, and after the dobutamine dosing tests. Analysis was performed separately for the ischaemic and nonischaemic dilated cardiomyopathy groups (Table 3 ). In both tested groups, the LK function was significantly reduced. Regional dyssynergy was significantly dilated in both groups. After a low dose of dobutamine, contractility was improved in both tested groups, with an increasing of number of segments identified as normokinetic versus segments with problematic kinetics. With a high dose of dobutamine, an evident increase in the number of segments with irregular kinetics was observed in patients with ischaemic dilated cardiomyopathy, whereas individuals from the other group exhibited further increases in the number of segments with normal kinetics. In regards to segment movement dynamics, an intergroup analysis (Bonferroni t-test) indicated a lack of statistically significant differences in the average number of normal segments between tested groups (p=0.084). Additionally, no distinction between these two groups in terms of the average number of normal segments was found after a low dobutamine dose treatment (p=0.067). At peak do- butamine doses (p=0.008) and after testing (p=0.039), statistically significant differences in the average number of normal segments were observed between patients with ischaemic and nonischaemic dilated cardiomyopathy. The average number of hypokinetic segments differed at statistically significant levels between the 2 tested patient groups at rest (p=0.03) and after testing (p=0.018), whereas, at low (p=0.0114) and peak dobutamine doses (p=0.505), so such differences were observed in the number of hypokinetic segments. For akinetic segments, significant differences in the average number of relevant segments were found at only peak doses of dobutamine (p=0.048).
LK wall collective mobility index (WMSI) values. The WMSI values were monitored for the two groups of patients at rest and after a low dose of dobutamine, peak dobutamine dose, and completion of testing. Two-factor repeated measures analysis of variance was used to compare the obtained index values. Variation in the WMSI values in this study resulted from differences in heart disease derivation, so we analysed the WMSI measurement time (at rest, at low doses of dobutamine, at peak dobutamine doses and after the test) and individual differences between patients. In this model, the measurement time was used as an intrasubject factor, and the difference be-tween ischaemic and nonischaemic dilated cardiomyopathy patients served as an intersubject factors. This analysis indicated a difference in the observed measurement times and in the dynamics of changes in WMSI values between observed groups at given measurement times. Significant differences were observed in the dynamic movement value of the calculated WMSI values, which were obtained by measuring parameters of wall mobility segment analysis before, during and after the test, between the two patient groups at given measurement times (two-way repeated measures ANOVA, measuring time *patients group; p=0.000). Differences between the WMSI average values were observed at various measurement times (two-way repeated measures ANOVA, measuring time; p=0.000) ( Table 4 , Graph 1). After an almost uniform change in the WMSI after a low dobutamine dose, the high dose of dobutamine provoked ischaemia in and worsened the kinetics of the group with ischaemic dilated cardiomyopathy. After the test, WMSI values were registered. We divided our patients into four groups ac- cording to their stress test results: group 1 for truly positive results (ischaemic heart disease and positive test, TPtrue positives), group 2 for truly negative results (patients with nonischaemic dilated cardiomyopathy and negative test, TN-true negatives), group 3 for false positive results (nonischaemic dilated cardiomyopathy and positive test, FP-false positives) and group 4 for false negative results (ischaemic heart disease and negative test, FN-false negatives). After creating 2x2 contingency tables, we calculated the following rates: TPR=TP/TP+FN and TNR=TN/ TN+FP. Sensitivity and specificity are widely accepted synonyms for TPR and TNR. Test sensitivity is an indicator of the test's ability to detect patients with ischaemic disease; in our case, the test sensitivity was 90% (CI=85-100%). Test specificity, which reflects the test's ability to identify healthy patients, was 98% (CI=96%-100%).
DISCUSSION
Differentiating between ischaemic and nonischaemic dilated cardiomyopathy is highly important (10, 11, 12, 13) , but the clinical aspect of these conditions can be very complicated. Ischaemia is likely the cause of cardiomyopathy in patients with myocardium infarct (IM) or aneurism LK. Nevertheless, some patients with ischaemic cardiomyopathy do not exhibit anamnestic or electrocardiographic signs of IM nor anamnestic data indicating chest pain but demonstrate more diffuse rather than regional hypocontractility of segments in ultrasound (14, 15) . In contrast, many patients with nonischaemic dilated cardiomyopathy often experience angina pain, and these patients' electrocardiograms contain features that match the signs of IM (11) . The main advantage of our research is the absolute confirmation of ischaemia in patients with dilated cardiomyopathy by FFR measurements, compared with other research that used only coronary graph results as an indicator of ischaemic disease aetiology, without reliable confirmation about the existence of ischaemia (7, 8) . In our research, we clearly demonstrated that in patients with LK dysfunction of unknown cause, regional dyssynergy upon receiving a peak dose of dobutamine clearly indicates an ischaemic aetiology of disease. In a carefully chosen group of patients, we confirmed that dobutamine stress echocardiography can differentiate two forms of dilated cardiomyopathies. We noticed that for nonischaemic dilated cardiomyopathies, contractility responses to dobutamine were not characterised by global hyperkinesia but rather mild and moderate improvements in contractility, which often limited to partial LK segments. Currently, other techniques are used to differentiate these two forms of dilated cardiomyopathies such as talium-201 scintigraphy at rest. However, loading and infusion of dipyridamole does not offer final solutions, whereas the use of positron emission tomography is limited by its price. New techniques and myocardium acquisition have not solved the problem of low applicability thus far (16, 17) . The interpretation of dyssynergy at rest is a well-known technique, due to infarct scarring, but often these large or real aneurysms can be caused by myocarditis. Mild to moderate dyssynergy is commonly observed with nonischaemic dilated cardiomyopathies and can be caused by hypoperfusion as a result of inadequate microcirculation (18, 19, 20) . In our study, basal hypocontractility in the ischaemic dilated cardiomyopathy group was less homogeneous than in the other group. In our research, we did not clearly separate necrotic myocardium from mixed myocardium, according to patient responses to dobutamine.
Electrocardiographic and haemodynamic data were not useful in our study for differentiating the two forms of cardiomyopathy. The response to a low dose of dobutamine was similar in both groups due to a favourable response from the largest number of hypokinetic segments. Nevertheless, this improvement in ischaemic cardiomyopathy spread to certain akinetic segments, which probably were part of the hibernating myocardium, whereas other segments remained dyssynergic. For a high dose of dobutamine in nonischaemic dilated cardiomyopathy patients, hypo-and akinetic segments maintained their previous improvement in kinetics, compared with the ischaemic disease group that exhibited a worsening in kinetics, with and without the presence of previous dyssynergy. The WMSI values also differed between tested groups at high doses of dobutamine, which was previously reported by Sharp et al. and Vign et al. (21, 3, 6) . In contrast to the aforementioned studies, we registered a significant increase in the WMSI when increasing from a low to high dose of dobutamine, with an especially effectual response in the nonischaemic dilated cardiomyopathy group, whereas the ischaemic diseases group exhibited different responses. Variations in the tested groups and different dobutamine infusion protocols (dobutamine dose, duration of each stage) can partially Graph 1. WMSI at the patients with ischemic and nonischemic dilated cardiomyopathy explain these discrepancies. In some undefined cases, intertwined factors of both forms of cardiomyopathies can be assumed to be responsible for false negative and false positive results (22, 23) . Extensive collaterals and inability to achieve adequate loads for this group of patients can explain the decreased test sensitivity. Patients with nonischaemic diseases often exhibit weak and limited responses in certain segments during dobutamine infusion. Registering a worsening of LK function for a high dose of dobutamine in the absence of coronary disease is likely the effect of the progressive phase of the myopathic process or simply a decreased coronary reserve (24, 25, 26) .
Limitations during the research. This study included several limitations. The number of patients was relatively small. We did not use relatively new technical modalities to improve endocardium visualisation. We did not consider right ventricle reactions to the infusion of dobutamine or right ventricle dimensions, based on the opinion that the left ventricle's function is preserved in ischaemic but not in nonischaemic dilated cardiomyopathies. The aetiology of dilated cardiomyopathy in single vessel coronary disease is disputable, as is the interpretation of results in these cases.
CONCLUSION
Dobutamine-atropine stress echocardiography is a comfortable patient testing method with very mild and rare side effects. The dynamics of LV segments in patients with ischaemic dilated cardiomyopathy exhibited significant differences during the individual stages of the test as a consequence of the test's ability to provoke ischaemia. The dynamics of LV segments in patients with nonischaemic (primary) dilated cardiomyopathy reflects the positive inotropic effect of dobutamine in healthy coronary vessels. Changes in the WMSI value during the test are a clear predictor of ischaemic heart disease in patients with severe LV dysfunction of unknown origin. The sensitivity of the test was 90%, and the specificity of the test was 98%, with the identification of actual ischaemic lesions in coronary blood vessels confirmed by FFR measurement.
Finally, patients with severe LV dysfunction are all different, and the possibility of coronary artery disease in patients with primary dilated cardiomyopathy should be noted.
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